Clinics in Dermatology
Volume 26, Issue 5 , Pages 486-502 , September 2008

Tumor necrosis factor antagonists in the therapy of psoriasis

  • Rotraut Mössner, MD

      Affiliations

    • Department of Dermatology, Georg-August University, von-Siebold-Str. 3, 37075 Göttingen, Germany
    • ,
  • Michael P. Schön, MD

      Affiliations

    • Rudolf Virchow Center, Deutsche Forschungsgemeinschaft Research Center for Experimental Biomedicine, Versbacher Str 9, 97078 Würzburg, Germany
    • Department of Dermatology, University of Würzburg, Josef-Schneider-Straße 2, 97080 Würzburg, Germany
    • Department of Dermatology and Venerology, University Medical Center Göttingen, von-Siebold Str 3, 37075 Göttingen, Germany
    • ,
  • Kristian Reich, MD

      Affiliations

    • Department of Dermatology, Georg-August University, von-Siebold-Str. 3, 37075 Göttingen, Germany
    • Dermatologikum, Stephansplatz 5, 20354 Hamburg, Germany
    • Corresponding Author InformationCorresponding author. Dermatologikum Hamburg, Stephansplatz 5, 20354 Hamburg, Germany. Tel.: +49 0 551 396427; fax: +49 0 551 396418.

References 

  1. Nickoloff BJ. The cytokine network in psoriasis. Arch Dermatol. 1991;127:871–884
  2. Nickoloff BJ, Xin H, Nestle FO, Qin JZ. The cytokine and chemokine network in psoriasis. Clin Dermatol. 2007;
  3. Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352:1899–1912
  4. Mössner R, Kingo K, Kleensang A, et al. Association of TNF-238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris. J Invest Dermatol. 2005;124:282–284
  5. Schön MP. Advances in psoriasis treatment. Lancet. 2005;366:1333–1335
  6. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti–TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995;7:251–259
  7. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003;124:1774–1785
  8. Di Sabatino A, Ciccocioppo R, Cinque B, et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut. 2004;53:70–77
  9. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367–1374
  10. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357:1842–1847
  11. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51:534–542
  12. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum. 2006;36:159–167
  13. Nestorov I, Zitnik R, DeVries T, et al. Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. Br J Clin Pharmacol. 2006;62:435–445
  14. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627–1632
  15. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014–2022
  16. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304–1312
  17. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598–606
  18. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ?. Semin Arthritis Rheum. 2005;34:12–18
  19. Humira 40mg prescribing information (Fachinformation). Abbot Laboratories, Kent, United Kingdom. June 2006.
  20. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279–3289
  21. Reich K, Nestle FO, Papp K, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol. 2006;154:1161–1168
  22. Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes. 2006;4:71
  23. Gladman DD, Mease PJ, Cifaldi MA, et al. Adalimumab improves joint- and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2007;66:163–168
  24. http://www.jnj.com/news/jnj_news/20070202_161407.htm. Accessed 13.01.2007.
  25. http://www.medicalnewstoday.com/medicalnews.php?Fnewsid-53536. Accessed 13.01.2007.
  26. http://www.medicalnewstoday.com/medicalnews.php?Fnewsid-55648. Accessed 13.01.2007.
  27. Hetland ML, Unkerskov J, Ravn T, et al. Routine database registration of biological therapy increases the reporting of adverse events twentyfold in clinical practice. First results from the Danish Database (DANBIO). Scand J Rheumatol. 2005;34:40–44
  28. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601–608
  29. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med. 2005;72:250–256
  30. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315–1324
  31. Infliximab. Remicade 100mg prescribing information (Fachinformation). Centocor, Leiden, the Netherlands. September 2006. Remicade 2006.
  32. Lelong J, Duburque C, Fournier C, et al. [Desensitisation to infliximab in patients with Crohn's disease]. Rev Mal Respir. 2005;22:239–246
  33. Enbrel 25mg prescribing information (Fachinformation). Berkshire (United Kingdom): Wyeth; 2006;
  34. Zeltser R, Valle L, Tanck C, et al. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol. 2001;137:893–899
  35. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–2285
  36. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54:2368–2376
  37. Tubach F, Ravaud P, Salmon-Ceron D, et al. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis. 2006;43:e95–e100
  38. Rychly DJ, DiPiro JT. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy. 2005;25:1181–1192
  39. Wallis RS, Broder M, Wong J, Lee A, Hoq L. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis. 2005;41(Suppl 3):S194–S198
  40. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol. 2006;2:602–610
  41. Atzeni F, Sarzi-Puttini P, Dell' Acqua D, et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther. 2005;8:R3
  42. De Rycke L, Baeten D, Kruithof E, et al. The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus. 2005;14:931–937
  43. De Bandt M, Sibilia J, Le LX, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7:R545–R551
  44. Misery L, Perrot JL, Gentil-Perret A, et al. Dermatological complications of etanercept therapy for rheumatoid arthritis. Br J Dermatol. 2002;146:334–335
  45. Phelan C, Wooltorton E. Infliximab and serious hematologic events. CMAJ. 2004;171:1045
  46. Montane E, Salles M, Barriocanal A, et al. Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges. Clin Rheumatol. 2007;26:1527–1529
  47. Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006;98:51–60
  48. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692–701
  49. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet. 2001;358:1042–1045
  50. Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol. 2003;120:211–216
  51. Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64:1421–1426
  52. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha—California, 2002-2003. MMWR Morb Mortal Wkly Rep. 2004;53:683–686
  53. Mazurek GH, Jereb J, Lobue P, et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep. 2005;54:49–55
  54. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005;42:315–322
  55. Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?. World J Gastroenterol. 2006;12:974–976
  56. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727–735
  57. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum. 2005;52:1227–1236
  58. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150–1157
  59. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264–2272
  60. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385–390
  61. Kavanaugh A, Antoni CE, Gladman DD, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis. 2006;65:1038–1043
  62. Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. 2006;33:712–721
  63. Hawrot AC, Metry DW, Theos AJ, Levy ML. Etanercept for psoriasis in the pediatric population: experience in nine patients. Pediatr Dermatol. 2006;23:67–71
  64. Papoutsaki M, Costanzo A, Massotta A, et al. Etanercept for the treatment of severe childhood psoriasis. Br J Dermatol. 2006;154:181–183
  65. Kress DW. Etanercept therapy improves symptoms and allows tapering of other medications in children and adolescents with moderate to severe psoriasis. J Am Acad Dermatol. 2006;54:S126–S128
  66. Farnsworth NN, George SJ, Hsu S. Successful use of infliximab following a failed course of etanercept in a pediatric patient. Dermatol Online J. 2005;11:11
  67. Menter MA, Cush JM. Successful treatment of pediatric psoriasis with infliximab. Pediatr Dermatol. 2004;21:87–88
  68. Esposito M, Mazzotta A, de Felice C, Papoutsaki M, Chimenti S. Treatment of erythrodermic psoriasis with etanercept. Br J Dermatol. 2006;155:156–159
  69. Heikkila H, Ranki A, Cajanus S, Karvonen SL. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis. Arch Dermatol. 2005;141:1607–1610
  70. Schmick K, Grabbe J. Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor-alpha antibody (infliximab). Br J Dermatol. 2004;150:367
  71. Kamarashev J, Lor P, Forster A, et al. Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept. Dermatology. 2002;205:213–216
  72. Trent JT, Kerdel FA. Successful treatment of Von Zumbusch pustular psoriasis with infliximab. J Cutan Med Surg. 2004;8:224–228
  73. Benoit S, Toksoy A, Bröcker EB, Gillitzer R, Goebeler M. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Br J Dermatol. 2004;150:1009–1012
  74. Callen JP, Jackson JH. Adalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescent. J Dermatolog Treat. 2005;16:350–352
  75. Rich SJ. Considerations for assessing the cost of biologic agents in the treatment of psoriasis. J Manag Care Pharm. 2004;10:S38–S41
  76. Sohn S, Schoeffski O, Prinz J, et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology. 2006;212:137–144
  77. Miller DW, Feldman SR. Cost-effectiveness of moderate-to-severe psoriasis treatment. Expert Opin Pharmacother. 2006;7:157–167
  78. Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003;349:658–665
  79. Jacobsson LT, Turesson C, Gulfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol. 2005;32:1213–1218
  80. Mössner R, Reich K. Infliximab in the treatment of psoriasis. Expert Rev Dermatol. 2006;1:515–526
  81. Reich K, Augustin M. Biologics in the treatment of psoriasis. Arzneimitteltherapie. 2005;23:384–397

☆ R. M. has received travel grants from Essex (Munich, Germany) and Wyeth (Münster, Germany). M. P. S. has received lecture fees from Serono (Munich, Germany), Wyeth, Essex, and Abbott (Wiesbaden, Germany), and research grants from Schering/Berlex (Richmond, Calif). K. R. has served as a consultant and paid speaker for Abbott, Biogen Idec (Tsamaning, Germany), Centocor (Horsham, PA), Essex, Schering-Plough (Kenilworth, NJ), Serono, and Wyeth. He has also received grant funding from Biogen Idec.

PII: S0738-081X(07)00254-4

doi: 10.1016/j.clindermatol.2007.10.030

Clinics in Dermatology
Volume 26, Issue 5 , Pages 486-502 , September 2008

Article Tools

* Image Usage & Resolution